This company listing is no longer active
Calliditas Therapeutics (CALTX) Stock Overview
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CALTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Calliditas Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 208.00 |
| 52 Week High | SEK 208.80 |
| 52 Week Low | SEK 80.80 |
| Beta | 1.46 |
| 1 Month Change | 0.29% |
| 3 Month Change | 1.07% |
| 1 Year Change | 114.43% |
| 3 Year Change | 115.32% |
| 5 Year Change | 263.64% |
| Change since IPO | 342.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| CALTX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.7% | 3.8% | 1.7% |
| 1Y | 114.4% | -15.5% | 12.5% |
Return vs Industry: CALTX exceeded the Swedish Pharmaceuticals industry which returned 65.9% over the past year.
Return vs Market: CALTX exceeded the Swedish Market which returned 21.2% over the past year.
Price Volatility
| CALTX volatility | |
|---|---|
| CALTX Average Weekly Movement | 0.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CALTX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CALTX's weekly volatility has decreased from 12% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 222 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) Fundamentals Summary
| CALTX fundamental statistics | |
|---|---|
| Market cap | SEK 11.18b |
| Earnings (TTM) | -SEK 480.36m |
| Revenue (TTM) | SEK 1.60b |
Is CALTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALTX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.60b |
| Cost of Revenue | SEK 104.68m |
| Gross Profit | SEK 1.50b |
| Other Expenses | SEK 1.98b |
| Earnings | -SEK 480.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 93.46% |
| Net Profit Margin | -30.00% |
| Debt/Equity Ratio | 920.0% |
How did CALTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/12 07:10 |
| End of Day Share Price | 2024/10/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Calliditas Therapeutics AB (publ) is covered by 6 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Dan Akschuti | Pareto Securities |
| Johan Unnerus | Redeye |